Objectives: Lucilia sericata maggots are successfully used for treating chronic wounds. As the healing process in these wounds is complicated by bacteria, particularly when residing in biofilms that protect them from antibiotics and the immune system, we assessed the effects of maggot excretions/ secretions (ES) on Staphylococcus aureus and Pseudomonas aeruginosa biofilms, the clinically most relevant species.
Introduction
Chronic wounds cause considerable morbidity and present the healthcare system with significant costs. 1 Such wounds are common in patients suffering from acute, extended trauma as well as patients with vascular insufficiencies and underlying chronic conditions such as diabetes mellitus 2, 3 in which even minor wounds become infected and show little tendency to heal. The healing process is often complicated by bacterial infections of the wound surface. 4 -6 Bacteria within chronic wounds often reside in biofilms 7 and these bacteria exhibit altered growth characteristics and gene expression profiles as compared with planktonic bacteria. 8 Biofilm formation has been associated with a number of diseases, such as endocarditis, 9 cystic fibrosis 10 and osteomyelitis. 11 An important practical consequence of biofilm formation is that the bacteria are protected against the actions of antibiotics 12, 13 and cells and effecter molecules of the immune system. 6, 14 Moreover, bacterial fragments/products released from biofilms will continuously attract host immune cells, like neutrophils, to the wound. As these cells cannot remove the infectious cause of inflammation, this will eventually lead to tissue destruction through the actions of bioactive products such as reactive oxygen species and proteases released by activated phagocytes. 15 Nowadays, the use of sterile larvae of the green bottle blowfly Lucilia sericata in the management of sores, ulcers and ‡These authors contributed equally to this study.
other chronic wounds is becoming increasingly widespread. 16 -18 Especially in trauma surgery, these maggots can prevent or at least reduce major disabling amputations. Maggots may contribute to wound healing by removing cell debris and non-viable tissue, 19 inhibiting the pro-inflammatory responses of phagocytes 20 and promoting tissue remodelling. 21 The molecules involved in these actions are believed to be contained in the excretions/secretions (ES) of the maggots. Interestingly, clinical observations have indicated that maggot therapy is more effective in patients with wounds infected with Gram-positive bacteria, such as Staphylococcus aureus, than those infected with Gram-negative bacteria, such as Pseudomonas aeruginosa. Additionally, more maggots are needed to accomplish healing of wounds infected with the latter bacterium. 22 Since modulation of bacterial biofilms will have a major impact on the healing process of chronically infected wounds, the aim of this study was to investigate the effects of ES on the formation of S. aureus and P. aeruginosa biofilms and on established biofilms.
Materials and methods

Maggots and maggot ES
ES of sterile second-and third-instar larvae of L. sericata (a kind gift from BioMonde GmbH, Barsbüttel, Germany) were collected as described previously. 20 In short, larvae were incubated in water for 60 min. Next, collected ES preparations were checked for sterility and stored at 2208C. For comparison, we also collected ES according to the method described by Kerridge et al.
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Bacterial strains and growth conditions S. aureus ATCC 29213 (Manassas, VA, USA) were grown in Tryptone Soya Broth (TSB) at 378C and P. aeruginosa PAO1 24 in Luria-Bertani (LB) medium at 288C, both under vigorous shaking.
The reporter bacteria Chromobacterium violaceum CVO26 25 and Escherichia coli DH5a strains pAK211 26 and pSB1075 27 were grown in LB medium at 288C.
Biofilm assay
Biofilm formation of S. aureus and P. aeruginosa in 96-well polyvinyl chloride plates was conducted as described previously. 28 In short, bacteria from overnight cultures were diluted with medium 1:1000 for S. aureus and 1:100 for P. aeruginosa and 5 mL aliquots of these bacterial suspensions were added to each well containing 100 mL of the medium with or without ES (range 0.2-20 mg): the medium for S. aureus was 0.5Â TSB supplemented with 0.2% (w/v) glucose and for P. aeruginosa 0.7Â M63 [10.5 mM (NH 4 ) 2 SO 4 , 62 mM KH 2 PO 4 , 28 mM K 2 HPO 4 , 0.14% glucose, 0.7 mM MgSO 4 and 0.37% casamino acids]. At the indicated intervals, planktonic cells were removed and the wells were washed with tap water. Subsequently, biofilms were exposed to a 1% (w/v) crystal violet solution for 15 min, washed and then incubated in absolute ethanol for 15 min to extract the crystal violet retained by the cells. Next, this solution was used to quantify the amount of biofilm by measuring its A 590 .
In addition, at various intervals after the start of the experiment, the planktonic cells were harvested and then the bacteria residing in these biofilms were recovered by sonicating three times for 15 s on ice with 30 s between each sonication step. Next, the number of viable bacteria in the suspensions of planktonic cells and of bacteria dispersed from the biofilms was determined microbiologically using serial dilutions of these suspensions plated in 6-fold dilutions onto COS blood agar plates. To investigate the effects of ES on established biofilms, we first formed biofilms for 24 h, then the planktonic cells were removed and 100 mL of medium with or without ES (range 0.2-20 mg) was added to the wells.
In vitro killing assay
To determine the bactericidal effect of ES on planktonic bacteria, in vitro killing assays were conducted as described previously. 29 Bacteria in mid-log phase were centrifuged at 2000 g for 10 min, washed with PBS and suspended in 10 mM sodium phosphate buffer ( pH 7.4) supplemented with 1% (v/v) TSB to a concentration of 1 Â 10 6 cells/mL. Subsequently, 200 mL of the bacterial suspension was transferred to Eppendorf tubes containing vacuum dried ES (range 2-400 mg). After 1 and 3 h, the number of surviving bacteria was determined microbiologically as described above.
Radial diffusion assay (RDA)
To further investigate the antibacterial activity of ES, we used the highly sensitive RDA as described previously 30 with minor modifications. In short, bacteria in mid-log phase were centrifuged at 2000 g for 10 min and washed with PBS. Next, 1 Â 10 5 bacteria/mL were dispersed in agar consisting of 1% (w/v) agarose (Sigma-Aldrich, St Louis, MO, USA) and 1% (w/v) TSB in 10 mM sodium phosphate buffer at 428C. Subsequently, the agar was poured into Petri dishes and solidified. Next, wells of 3 mm in diameter were made in this agar and 5 mL of vacuum dried ES (range 2-400 mg) solubilized in 0.01% (v/v) acetic acid were transferred to the wells. After 3 h of incubation, an overlay agar was poured on top of the bacterial agar. The following day, the diameters of the growth inhibition zones were measured. We validated the assay using human neutrophil peptides 1-3 (HNP1-3) (isolated from human neutrophils) and the synthetic lactoferrin-derived peptide, hLF 1 -11 , 29 both at a concentration of 50 mg/L.
Detection of autoinducer activity
Autoinducer activity was measured using the reporter strains C. violaceum CVO26 and E. coli DH5a containing pAK211 or pSB1075 as described previously. 31 In short, bacteria were grown overnight in LB medium supplemented with, respectively, kanamycin (25 mg/L), chloramphenicol (20 mg/L) or carbomycin (200 mg/L). Subsequently, plates were overlaid with top agar consisting of LB medium containing 0.8% (w/v) agar (Bacto TM agar, BD, Sparks, MD, USA) and 10 mL of the bacterial suspension per mL. Next, 5 mL of vacuum dried ES (range 2-400 mg) solubilized in water or, as a negative control, only water was transferred to the agar and incubated at 288C for 16 h. As a positive control, 0.5 mg of synthetic acyl homoserine lactone autoinducers (kindly provided by Professor P. Williams, University of Nottingham, UK) was used. Autoinducer activity was detected by the production of a purple pigment (violacein) by C. violaceum and by the emission of light when using E. coli after applying a Fuji medical X-Ray (Fuji Photo Film Co., Ltd, Tokyo, Japan) on the plates.
Statistical analysis
Results are means + SEM of at least three experiments using in each experiment two different batches of ES. Differences between the values for ES-exposed and non-exposed bacteria were analysed using a one-way ANOVA with Dunnett's post-test for multiple comparisons. The level of significance was set at P , 0.05. van der Plas et al.
Results
Effect of ES on biofilm formation
To find out whether ES can prevent biofilm formation, we determined the amount of biofilm at various intervals after addition of 0 -20 mg of ES. The results revealed that after a lag time of 8 h, S. aureus started to form a detectable biofilm and that the biofilm formation levelled off after 14 h (Figure 1a ). In addition, as little as 0.2 mg of ES completely blocked S. aureus biofilm formation. The kinetics of P. aeruginosa biofilm formation during the first 24 h was similar to that found for S. aureus, but thereafter P. aeruginosa biofilms became unstable in several experiments (Figure 1b) . Furthermore, enhanced P. aeruginosa biofilm formation was seen at 8 -10 h after addition of 2 and 20 mg of ES, but thereafter the biofilms formed in the presence of 20 mg of ES, but not 2 mg of ES, collapsed. In agreement, we observed that the number of bacteria in the biofilms exposed to ES for 8 -10 h was almost 10-fold higher than in unexposed biofilms (Table 1) . Further experiments with higher doses of ES (up to 100 mg) revealed that the start of the P. aeruginosa biofilm breakdown was dosedependently enhanced by ES, yet all these biofilms were broken down within 48 h (data not shown). In addition, replacing the medium of biofilms developed in the presence of 20 mg of ES for 8 h with fresh ES-containing medium resulted after 24 h in the breakdown of P. aeruginosa biofilms, whereas no breakdown was seen in the wells reincubated with medium alone, indicating that components in ES degraded the biofilms. Of note, S. aureus formed biofilms mostly on the bottom of the wells whereas P. aeruginosa formed biofilms on the wall of the wells at the air -liquid interface (Figure 1a and b, inserts) . Interestingly, treatment of 20 mg of ES for 2 h at 1008C completely abrogated the effects on S. aureus biofilm formation, but not on P. aeruginosa biofilm formation (Table 2 ), indicating that different molecules within ES modulate S. aureus and P. aeruginosa biofilm formation.
Effect of ES on established biofilms
Next, we determined the effects of ES on established biofilms. The results showed that within 2 h after addition of ES, the amount of S. aureus biofilm was dose-dependently reduced and a complete breakdown was seen with 2 and 20 mg of ES (Figure 2a) . Furthermore, 0.2 mg of ES gradually reduced the amount of biofilm within the first 6 h and thereafter the amount of biofilm remained constant. Established P. aeruginosa biofilms were initially stimulated by ES and after 10 h gradually broken down by 20 mg of ES, whereas 2 mg of ES did not cause an effect (Figure 2b ). Heat-treatment of ES completely abrogated their effects on established S. aureus biofilms, but not on established P. aeruginosa biofilms ( Table 2) . Results are means + SEM of four to six experiments. 'no' indicates that no biofilm was detectable. *Significant (P , 0.05) differences between the values for bacteria exposed to ES and those for non-exposed bacteria. 
Effect of ES on bacterial viability
Since ES may have bactericidal activities against Gram-positive and Gram-negative bacteria, 23, 32 we determined the effect of ES on the number of viable biofilm-associated and planktonic S. aureus and P. aeruginosa in our experiments. The results revealed that with the current doses and conditions ES did not kill planktonic bacteria or reduce the total number of bacteria in the wells (Table 1) , making it unlikely that ES disrupts biofilms by killing the bacteria. Furthermore, 20 mg of ES was not bactericidal against S. aureus and P. aeruginosa in in vitro killing assays and RDAs. In vitro killing experiments revealed that only the largest dose of ES studied (400 mg) reduced the number of viable S. aureus after 3 h by 73 + 10%, but not after 1 h, as compared with the control (n ¼ 7). Using RDAs we found that ES killed S. aureus in a dose-dependent fashion with as little as 40 mg of ES being effective (Figure 3 ). Heat-treatment abolished the bactericidal effects of ES on S. aureus in the in vitro killing assays and it reduced the effects in the RDAs by 79 + 16% (n ¼ 4). In contrast, ES (up to 800 mg) did not reduce the number of viable P. aeruginosa. Finally, no differences in the antibacterial activity between ES preparations obtained by the method of Kerridge et al. 23 and our ES preparations were noted.
Effect of ES on quorum sensing systems of Gram-negative bacteria
As quorum sensing systems control bacterial functions, such as biofilm formation, 33 interference with these bacterial systems could explain the effects of ES on biofilms. Therefore, we determined the ability of ES to mimic or antagonize the actions of various N-acyl homoserine lactones (AHLs) using specific reporter bacteria. The results showed that ES (0.2-200 mg) had neither mimicking nor antagonizing effects on quorum sensing systems detecting short chain (C6/C8) AHLs, as assayed with the reporter bacteria C. violaceum CVO26 and E. coli DH5a containing pAK211. The positive control (synthetic C6 AHLs) showed zones of $5 cm in both systems (n ¼ 3). Furthermore, ES had no effect on quorum sensing systems responding to long chain (C10/C12) AHLs assayed in E. coli DH5a containing pSB1075; the positive control (synthetic C10 AHLs) caused a zone of 5 + 0.4 cm (n ¼ 3).
Discussion
The main conclusion from the present study is that maggot ES are differentially effective against biofilms of S. aureus and P. aeruginosa. This conclusion is based on the following observations. First, S. aureus biofilm formation was blocked by as little as 0.2 mg of ES per well, whereas 2 mg of ES per well was sufficient to degrade established biofilms within 2 h. Secondly, P. aeruginosa biofilm formation was initially enhanced by ES and after 10 h biofilms treated with 20 mg of ES, but not 2 mg of ES, degraded and during the remaining period of the analysis no biofilms could be detected. Interestingly, others reported similar effects of the prokaryotic predator Micavibrio aeruginosavorus van der Plas et al.
on P. aeruginosa biofilm formation and suggested that increased cell -cell interactions may explain the initial enhancement of biofilms. 34 Thirdly, the doses of ES used in this study were within the therapeutic range, i.e. those present at the surface of maggot-treated wounds. 35, 36 For instance, 20 mg of ES was obtained after incubating $10 maggots in distilled water for 1 h. It should be realized that in our in vitro experiments ES were added only once to the bacteria and/or bacterial biofilms, whereas in wounds, maggots are continuously present. Furthermore, ES were obtained from sterile maggots. Since it is likely that ES of maggots exposed to bacteria in a wound have an altered composition, it is of interest that ES obtained from bacteria-exposed maggots were as effective against bacterial biofilms as sterile ES (M. J. A. van der Plas and S.-W. Wai unpublished observations).
The second conclusion pertains to the mechanism(s) underlying the prevention of biofilm formation and the breakdown of bacterial biofilms by ES. The possibility that ES modulate biofilms simply by killing the bacteria is highly unlikely since in our biofilm experiments ES did not affect the number of viable bacteria in the wells. Since others 23, 32, 37 using suspension assays or RDAs reported that ES have bactericidal properties against planktonic bacteria, we attempted to confirm the bactericidal activity of ES using the same methodology. The most sensitive assay of the two is the RDA, although the in vitro killing assay closely resembles the suspension assay in our biofilm experiments. In agreement with our data from experiments with bacteria in biofilm assays, these amounts of ES did not affect S. aureus viability and P. aeruginosa was not killed by ES even at very high amounts (up to 800 mg). It should be realized that the amounts of ES used by others were either not indicated 32, 37 or therapeutically irrelevant. 23 Investigation into the effects of ES on quorum sensing signalling pathways in several Gram-negative reporter strains showed that ES do not mimic or antagonize short-and long-chain AHLs. However, these data do not exclude the possibility that ES interfere with quorum sensing signalling of bacteria in the wound. Although no definitive explanation for the differences in effects of ES on S. aureus and P. aeruginosa biofilms can be offered on the basis of our data, we concluded that the observed effects are mediated by different molecules and mechanisms, since heat-treatment completely abrogated the effects of ES on S. aureus, but not on P. aeruginosa, biofilms. This suggests that proteins or heatsensitive peptides within ES may be responsible for the breakdown of S. aureus, but not of P. aeruginosa, biofilms. More research, including purification of these compounds, is needed to gain a detailed understanding of the mechanisms involved in the modulatory effects of ES on biofilms.
We are the first to report that ES disrupt bacterial biofilms. It should be kept in mind that more ES required to disrupt P. aeruginosa biofilms than S. aureus biofilms and that low doses of ES can result in enhancement of P. aeruginosa biofilms. In addition, it has been shown in vitro that P. aeruginosa, but not S. aureus, impairs maggot survival. 38 Together, these data are in agreement with clinical findings, 22 indicating that more maggots should be used for wounds infected with P. aeruginosa (compared with S. aureus). Furthermore, as a result of biofilm breakdown, the bacteria become susceptible to actions of antibiotics and the immune system as well as to actions of maggots. 39 Therefore, ES (especially in combination with antibiotics) are a very promising source of candidates for the development of new treatments for biofilm-associated diseases, including cystic fibrosis, infected medical devices, such as catheters and prostheses, and chronic wounds.
